Zhejiang Hisun Pharmaceutical Full Year 2023 Earnings: CN¥0.08 loss per share (vs CN¥0.42 profit in FY 2022)

Zhejiang Hisun Pharmaceutical (SHSE:600267) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥10.4b (down 14% from FY 2022).
• Net loss: CN¥93.2m (down by 119% from CN¥489.0m profit in FY 2022).
• CN¥0.08 loss per share (down from CN¥0.42 profit in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zhejiang Hisun Pharmaceutical Earnings Insights

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 9.8% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Zhejiang Hisun Pharmaceutical that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.